logo-loader
Oncimmune

Appointment of Joint Broker

/**/ h1{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Arial","sans-serif";color:#2F5496;font-weight:normal;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .ae{size:595.05pt 840.85pt;margin:101.6pt 91.1pt 72.0pt 99.95pt;}div.ae{}p.as{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify}span.aq{font-size:11.0pt}p.at{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: center}p.au{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-div: italic; font-weight: bold; text-align: center}p.av{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";text-align:justify}span.aa{}p.aw{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify; vertical-align: baseline}span.ak{font-size:11.0pt;color:black} span.ax{color:#0563C1;font-size:11.0pt;color:black}span.ay{color:#0563C1;text-decoration:underline;font-size:11.0pt;color:black}p.az{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; margin-left: -7.1pt; text-align: justify}p.ba{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";margin-left:-7.1pt;text-align:justify;text-indent: 7.1pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";}p.ag{ font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}span.ah{font-size:11.0pt;font-family:"Arial","sans-serif"}span.af{font-size:11.0pt; color:black} /**/
RNS Number : 1641N
Oncimmune Holdings PLC
20 September 2019
 

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

 

Appointment of Joint Broker

 

 

September 20, 2019 - Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, is pleased to announce that finnCap Limited has been appointed a Joint Broker to the Company, with immediate effect.

 

 

For further information:

 

Oncimmune Holdings plc

Matthew Hall, Chief Financial Officer

[email protected]

 

Cléa Rosenfeld, Head of Investor Relations

[email protected]

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

+44 (0)20 3829 5000

 

finnCap Limited (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

+44 (0)20 7220 0500

 

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

 

Media enquiries:

FTI Consulting

Brett Pollard, Andrew Ward

[email protected]

+44 (0)20 3727 1000

 

 

About Oncimmune

 

Beating cancer, one test at a time

 

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

 

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT® Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

 

What is EarlyCDT Lung?

 

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

 

For more information, visit www.oncimmune.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPPGUUWBUPBGWU

Quick facts: Oncimmune

Price: 50.5

Market: AIM
Market Cap: £31.94 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

2 weeks ago